Table 2.
30 highest-ranked global clinical research contributions for COVID-19 trials (conducted in a single country nationally and conducted in multiple countries internationally; based on 4,673 RCTs registered as of February 28, 2022).
|
National contribution only (n = 4,673) |
National and international contribution (n = 4,673) |
|||
|---|---|---|---|---|
| Rank | Countries | N (%) | Countries | N (%) |
| 1 | Iran | 615 (13.2%) | USA | 825 (17.7%) |
| 2 | International | 611 (13.1%) | Iran | 619 (13.2%) |
| 3 | USA | 605 (12.9%) | India | 566 (12.1%) |
| 4 | India | 506 (10.8%) | China | 353 (7.6%) |
| 5 | China | 344 (7.4%) | Spain | 309 (6.6%) |
| 6 | Spain | 193 (4.1%) | Brazil | 273 (5.8%) |
| 7 | France | 139 (3%) | United Kingdom | 211 (4.5%) |
| 8 | Brazil | 136 (2.9%) | France | 209 (4.5%) |
| 9 | Egypt | 88 (1.9%) | Mexico | 159 (3.4%) |
| 10 | Italy | 82 (1.8%) | Italy | 148 (3.2%) |
| 11 | Japan | 77 (1.6%) | Canada | 134 (2.9%) |
| 12 | Canada | 73 (1.6%) | Germany | 119 (2.5%) |
| 13 | Germany | 61 (1.3%) | Japan | 117 (2.5%) |
| 14 | Mexico | 57 (1.2%) | Argentina | 101 (2.2%) |
| 15 | Turkey | 54 (1.2%) | Russia | 98 (2.1%) |
| 16 | Australia | 53 (1.1%) | Egypt | 97 (2.1%) |
| 17 | Thailand | 49 (1%) | Belgium | 83 (1.8%) |
| 18 | Russia | 47 (1%) | Australia | 79 (1.7%) |
| 19 | Denmark | 41 (0.9%) | Turkey | 78 (1.7%) |
| 20 | Netherlands | 41 (0.9%) | Colombia | 73 (1.6%) |
| 21 | Pakistan | 37 (0.8%) | Netherlands | 71 (1.5%) |
| 22 | Belgium | 34 (0.7%) | Denmark | 68 (1.5%) |
| 23 | Argentina | 29 (0.6%) | Thailand | 66 (1.4%) |
| 24 | Cuba | 28 (0.6%) | Peru | 64 (1.4%) |
| 25 | Indonesia | 28 (0.6%) | Poland | 64 (1.4%) |
| 26 | Bangladesh | 25 (0.5%) | South Korea | 56 (1.2%) |
| 27 | Israel | 24 (0.5%) | Ukraine | 50 (1.1%) |
| 28 | Sweden | 24 (0.5%) | Pakistan | 49 (1%) |
| 29 | Colombia | 22 (0.5%) | Israel | 45 (1%) |
| 30 | Poland | 18 (0.4%) | Indonesia | 43 (0.9%) |
Of note, 241 registered trials did not report the countries of conduct.